Detail akcie Phylogica online

Business Summary: PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. The Company utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002). The Company's VP-001 program is a lead asset for a blinding eye disease of childhood progressed through multiple patient cohorts in the ongoing single ascending dose clinical trial. ADOA is a progressive and blinding eye disease.
Financial Summary: BRIEF: For the fiscal year ended 30 June 2025, PYC Therapeutics Ltd revenues increased 15% to A$26.2M. Net loss increased 33% to A$50.3M. Revenues reflect R&D tax incentive increase of 34% to A$23.5M, Interest income increase from A$796K to A$2.7M. Higher net loss reflects Research & Development Expense - Balanci increase of 24% to A$57.7M (expense), Employee benefits expenses increase of 24% to A$12.3M (expense).